EA202191541A1 - ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ - Google Patents
ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯInfo
- Publication number
- EA202191541A1 EA202191541A1 EA202191541A EA202191541A EA202191541A1 EA 202191541 A1 EA202191541 A1 EA 202191541A1 EA 202191541 A EA202191541 A EA 202191541A EA 202191541 A EA202191541 A EA 202191541A EA 202191541 A1 EA202191541 A1 EA 202191541A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- organophosphate
- therapeutic applications
- substituted compounds
- met inhibitors
- triazolo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- 229940122661 MET tyrosine kinase inhibitor Drugs 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- -1 [1.2.4]triazolo[4 Chemical compound 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5004—Acyclic saturated phosphines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779960P | 2018-12-14 | 2018-12-14 | |
| PCT/US2019/066414 WO2020124060A1 (en) | 2018-12-14 | 2019-12-14 | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191541A1 true EA202191541A1 (ru) | 2022-01-21 |
Family
ID=71077551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191541A EA202191541A1 (ru) | 2018-12-14 | 2019-12-14 | ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12258365B2 (https=) |
| EP (1) | EP3893872B1 (https=) |
| JP (1) | JP2022513215A (https=) |
| KR (1) | KR20210111779A (https=) |
| CN (1) | CN113412112B (https=) |
| AU (1) | AU2019395282A1 (https=) |
| BR (1) | BR112021011547A2 (https=) |
| CA (1) | CA3122575A1 (https=) |
| EA (1) | EA202191541A1 (https=) |
| IL (1) | IL283589A (https=) |
| MX (1) | MX2021006982A (https=) |
| SG (1) | SG11202105872RA (https=) |
| TW (1) | TW202039500A (https=) |
| WO (1) | WO2020124060A1 (https=) |
| ZA (1) | ZA202104000B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116969955B (zh) * | 2023-09-25 | 2023-12-19 | 中国药科大学 | 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170103T1 (hr) | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| US20110039856A1 (en) * | 2007-11-29 | 2011-02-17 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| EA030141B1 (ru) | 2009-12-31 | 2018-06-29 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| ES2598530T3 (es) | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| ES2877799T3 (es) * | 2015-12-31 | 2021-11-17 | Shanghai Pharmaceuticals Holding Co Ltd | Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones |
-
2019
- 2019-12-14 EA EA202191541A patent/EA202191541A1/ru unknown
- 2019-12-14 BR BR112021011547-1A patent/BR112021011547A2/pt not_active IP Right Cessation
- 2019-12-14 AU AU2019395282A patent/AU2019395282A1/en not_active Abandoned
- 2019-12-14 JP JP2021533641A patent/JP2022513215A/ja active Pending
- 2019-12-14 SG SG11202105872RA patent/SG11202105872RA/en unknown
- 2019-12-14 CA CA3122575A patent/CA3122575A1/en not_active Abandoned
- 2019-12-14 US US17/312,669 patent/US12258365B2/en active Active
- 2019-12-14 MX MX2021006982A patent/MX2021006982A/es unknown
- 2019-12-14 EP EP19897455.2A patent/EP3893872B1/en active Active
- 2019-12-14 CN CN201980091722.3A patent/CN113412112B/zh active Active
- 2019-12-14 WO PCT/US2019/066414 patent/WO2020124060A1/en not_active Ceased
- 2019-12-14 KR KR1020217022048A patent/KR20210111779A/ko not_active Withdrawn
- 2019-12-16 TW TW108146055A patent/TW202039500A/zh unknown
-
2021
- 2021-05-31 IL IL283589A patent/IL283589A/en unknown
- 2021-06-10 ZA ZA2021/04000A patent/ZA202104000B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113412112A (zh) | 2021-09-17 |
| EP3893872B1 (en) | 2024-07-17 |
| KR20210111779A (ko) | 2021-09-13 |
| CN113412112B (zh) | 2024-06-11 |
| TW202039500A (zh) | 2020-11-01 |
| WO2020124060A1 (en) | 2020-06-18 |
| SG11202105872RA (en) | 2021-07-29 |
| EP3893872A4 (en) | 2022-08-10 |
| EP3893872A1 (en) | 2021-10-20 |
| US12258365B2 (en) | 2025-03-25 |
| MX2021006982A (es) | 2021-09-10 |
| AU2019395282A1 (en) | 2021-07-08 |
| ZA202104000B (en) | 2022-08-31 |
| BR112021011547A2 (pt) | 2021-08-31 |
| CA3122575A1 (en) | 2020-06-18 |
| US20220064194A1 (en) | 2022-03-03 |
| IL283589A (en) | 2021-07-29 |
| JP2022513215A (ja) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39477A (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| CY1125460T1 (el) | Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| JOP20190076A1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| MX2021003517A (es) | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| NZ758243A (en) | Indole ahr inhibitors and uses thereof | |
| EA201290237A1 (ru) | Киназные ингибиторы | |
| EA201791011A1 (ru) | 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| AR089641A1 (es) | COMPUESTOS BICICLICOS Y SUS USOS COMO INHIBIDORES DUALES DE c-SRC/JAK | |
| EA202091475A1 (ru) | ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| EA201892436A1 (ru) | Пиримидиновые соединения в качестве ингибиторов jak киназы | |
| EA201891067A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ | |
| EA201300997A1 (ru) | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ | |
| EP3765462A4 (en) | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE AND IMIDAZO [1, 2-B] PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| NI202000100A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| CO2019002171A2 (es) | Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos. | |
| EA201791743A1 (ru) | Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов |